Systemic Anti-Cancer Therapy Regimen Library
SAR STS Advanced - trabectedin
Treatment Overview
Cycle 1 (and all further cycles) - 21 days
Cycle details
Cycle 1 (and all further cycles) - 21 days
| Medication | Dose | Route | Days | Max Duration |
|---|---|---|---|---|
| dexamethasone * | 20 mg | intravenous | 1 | 15 minutes |
| dexamethasone * | 8 mg | oral administration | 2, 3 | |
| ondansetron | 8 mg Twice daily | oral administration | 1, 2 | |
| trabectedin | 1.5 mg/m² | intravenous | 1 | 24 hours Min: 24 hours |
| domperidone | 10 mg Three times daily | oral administration | 1 |
Full details
Cycle 1 (and all further cycles) - 21 days
Day: 1
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| dexamethasone * | 20 mg | intravenous | 15 minutes |
Instructions:
30 minutes prior to trabectedin as prophylaxis for hepatotoxicity, excessive myelosuppression and hypersensitivity reactions. |
| ondansetron | 8 mg Twice daily | oral administration |
Instructions:
ONE hour prior to chemotherapy and then every 12 hours. |
|
| trabectedin | 1.5 mg/m² | intravenous | 24 hours Min: 24 hours |
Instructions:
Administered by continuous infusion over 24 hours.
|
| domperidone | 10 mg Three times daily | oral administration |
Instructions:
When required for nausea and/or vomiting. The choice of rescue antiemetic may be substituted to reflect institutional policy or individual patient characteristics. |
Day: 2
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| dexamethasone * | 8 mg | oral administration |
Instructions:
ONCE daily in the morning with food. Dose and duration may be individualised at clinician’s discretion. |
|
| ondansetron | 8 mg Twice daily | oral administration |
Instructions:
Every 12 hours. |
Day: 3
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| dexamethasone * | 8 mg | oral administration |
Instructions:
ONCE daily in the morning with food. Dose and duration may be individualised at clinician’s discretion. |
Supportive Care Factors
| Factor | Value |
|---|---|
| Emetogenicity: | Medium |
| Hypersensitivity / Infusion related reaction risk: | High - routine premedication recommended |
References
Janssen Products Limited. Yondelis U.S. Prescribing Information. June 2020. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/YONDELIS-pi.pdf (Accessed 22 September 2021).
Pharma Mar, S.A. Yondelis Product information 03 August 2012 https://www.ema.europa.eu/en/documents/product-information/yondelis-epar-product-information_en.pdf (accessed 24 November 2022).
* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.
s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.